DRAP Strengthens Pharmacovigilance in Sindh

newsdesk
2 Min Read
DRAP and WHO trained 120+ officers in Pharmacovigilance Pakistan and VigiFlow on 22 Dec 2025 to boost adverse event reporting across Sindh.

The Drug Regulatory Authority of Pakistan partnered with the World Health Organization to deliver a one-day training on pharmacovigilance and VigiFlow data entry on 22 December 2025 at the United Medical & Dental College in Karachi. The programme drew more than 120 participants as part of ongoing efforts to strengthen pharmacovigilance Pakistan and expand capacity at provincial and hospital levels.

Attendees included pharmacovigilance officers nominated by the Sindh Health Department serving at DHQ and Civil Hospitals, taluka-level hospitals and several private sector hospitals across Sindh. The training focused on improving adverse event reporting workflows and practical data entry skills to ensure timely and accurate submission of safety reports into national systems.

Dr Obaidullah, CEO of DRAP, highlighted the central role of provincial pharmacovigilance centres and hospitals as the first point of contact for reporting adverse events, and reiterated DRAP’s commitment to support provinces in scaling up pharmacovigilance Pakistan initiatives. The message underscored the importance of local reporting networks for national drug safety monitoring.

Officers from the National Pharmacovigilance Centre at DRAP delivered sessions on core pharmacovigilance practices while representatives from the Uppsala Monitoring Centre presented on the Vigiverse platform. A live demonstration of the VigiFlow database gave participants hands-on exposure to case entry and management tools widely used for signal detection and regulatory follow-up.

By equipping hospital officers with practical skills and reinforcing collaboration between DRAP, provincial centres and international partners, organisers say the training will contribute to more effective adverse event reporting and overall drug safety surveillance in Pakistan.

Share This Article
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *